期刊文献+

促性腺激素释放激素拮抗剂方案中卵巢反应性相关因素分析 被引量:5

Relative factors of ovarian response in GnRH-ant protocol
下载PDF
导出
摘要 目的研究促性腺激素释放激素拮抗剂(GnRH-ant)方案中卵巢反应性的影响因素及其与妊娠结局的关系。方法分析因输卵管因素和(或)男方因素在我院生殖中心进行体外受精/卵胞浆内单精子注射(IVF/ICSI)助孕的患者共452个周期,按患者的卵巢反应性分为卵巢低反应组、正常反应组和高反应组,比较拮抗剂方案中患者的一般情况、内分泌激素水平、促性腺激素(Gn)用药时间和剂量、获卵数、受精率及临床妊娠结局,并分析上述因素与卵巢反应性的关系。结果(1)在卵巢低反应组、正常反应组和高反应组中,患者的年龄、基础卵泡刺激素(bFSH)水平、基础睾酮(T)水平、窦卵泡计数(AFC)之间差异有统计学意义(P<0.05)。(2)三组患者人绒毛膜促性腺激素(HCG)日的雌二醇(E_2)水平、Gn的用量、取卵数、移植数、冷冻数及流产率之间差异有统计学意义(P<0.05);Gn的用药时间、子宫内膜厚度之间差异无统计学意义(P>0.05);卵巢低反应组的临床妊娠率(30.28%)明显低于其他两组,差异有统计学意义(P<0.05)。(3)多因素Logistic回归显示,年龄、bFSH水平及总Gn用量与卵巢反应性呈负相关,取卵数与卵巢反应性呈正相关。结论拮抗剂方案中,卵巢反应性与患者的年龄、bFSH水平及Gn用量有关,对卵巢反应性进行评估应当结合患者的一般情况、超声学检查及内分泌特点等多因素进行综合分析。 Objective: To study the effective factors of ovarian response and its relationship with pregnancy outcomes in gonadotropin-releasing hormone antagonists(GnRH-ant)protocol. Methods. The women who underwent in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) therapy due to tubal and/or male factors were included in this study. 452 controlled ovarian stimulation cycles were analyzed. According to ovarian response, all the patients were divided into three groups, the poor ovarian response (POR) group, the normal ovarian response (NOR) group and the high ovarian response (HOR) group. Women's general characteristics, basal and HCG day hormone levels, duration of controlled ovarian hyperstimulation (COH) and dosage of ganadotropin (Gn), retrieved oocytes, fertilization rate, transfer embryos, pregnant outcomes were evaluated in GnRH-ant protocol. The relative factors with ovarian response were analyzed by multi-factor Logistic regression. Results: (1) There were significant differences on age, serum basal follicle-stimulating hormone (bFSH), serum basal testosterone (T), antral follicle count (AFC) among the three groups (P〈0.05).(2) The significant differences were found in levels of estradiol (E2) on HCG day, dosage of Gn, retrieved oocytes, transfer embryos and miscarriage rate (P〈0.05). There was no significant difference in duration of COH, endometrium thickness among the three groups (P〉0.05). Compared to the other groups, the clinical pregnancy rate (30. 28%) in POR group was significantly lower (P〈0.05). (3) Multiple factors Logistic regression analysis demonstrated that age, bFSH levels and dosage of Gn were negatively correlated with ovarian response, and the number of retrieval oocytes was positively related to ovarian response. Conclusions: Ovarian response is associated with the age, bFSH level and dosage of ganadotropins in COH of women who undergo IVF/ICSI with GnRH-ant protocol. It should combine with general characteristics, ultrasonic examination, endocrine features and Gn reactivity to comprehensive evaluate ovarian response in COH.
出处 《生殖医学杂志》 CAS 2013年第11期841-845,共5页 Journal of Reproductive Medicine
基金 国家自然科学基金项目(81170542) 北京市卫生系统高层次人才培养项目(2011-3-071)
关键词 卵巢反应性 控制性促排卵 GnRH—ant方案 妊娠结局 Ovarian response Controlled ovarian hyperstimulation GnRH-ant protocol Pregnancy outcome
  • 相关文献

参考文献14

  • 1Felberbaum RE, Diedrich K. Gonadotrophin-releasinghormone antagonists : will they replace the agonists? [ J/OL]. Reprod Biomed Online?2003?6:43-53.
  • 2Ferraretti AP, La Marca A,Fauser BC, et al. ESHREconsensus on the definition of , poor response, to ovarianstimulation for in vitro fertilization:the Bologna criteria [J],Hum Reprod,2011,26: 1616-1624.
  • 3Sunkara SK,Rittenberg V,Raine-Fenning N, et al.Association between the number of eggs and live birth in IVFtreatment:an analysis of 400,135 treatment cycles [J], HumReprod,2011,26:1768-1774.
  • 4Chen CH, Zhang X, Barnes R? et al. Relationship betweenpeak serum estradiol levels and treatment outcome in in vitrofertilization cycles after embryo transfer on day 3 or day 5[J]. Fertil Steril,2003,80:75-79.
  • 5eyhan A’Ata B. The role of corifollitropin alfa in controlledovarian stimulation for IVF in combination with GnRHantagonist [J], Int J Womens Health,2011,3 :243-255.
  • 6Yarali H,Esinler I, Polat M,et al. Antagonist/letrozoleprotocol in poor ovarian responders for intracytoplasmicsperm injection:a comparative study with the microdose flare-up protocol [J]. Fertil Steril,2009192:231-235.
  • 7Tarlatzis BC,Zepiridis L,Grimbizis G, et al. Clinicalmanagement of low ovarian response to stimulation for IVF ? asystematic review [J]. Hum Reprod Update,2003,9 j61-76.
  • 8Homburg R. Management of infertility and prevention ofovarian hyperstimulation in women with polycystic ovarysyndrome [J]. Best Pract Res Clin Obstet Gynaecol, 2004,18:773-788.
  • 9Lainas TG,Sfontouris IA,Zorzovilis IZ,et al. Flexible GnRHantagonist protocol versus GnRH agonist long protocol inpatients with polycystic ovary syndrome treated for IVF : aprospective randomised controlled trial (RCT) [ J ]. HumReprod,2010,25:683-689.
  • 10Lainas GT,Kolibianakis EM?Sfontouris IA?et al. Outpatientmanagement of severe early OHSS by administration ofGnRH antagonist in the luteal phase:an observational cohortstudy [J]. Reprod Biol Endocrinol,2012,10:69.

同被引文献39

  • 1Broekmans FJ, Kwee J, Hendriks D J, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome[J]. Hum Reprod Update, 2006, 12:685-718.
  • 2Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development[J]. Reproduction, 2006, 132:191-206.
  • 3Hamdine O, Eijkemans MJ, Lentjes EW, Torrance IIL, Macklon NS, Fauser BC, Broekmans FJ. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Mullerian hormone[J]. Hum Reprod, 2014.
  • 4Lin PY, Huang FJ, Kung Fr, Chiang HJ, Lin YJ, Lin YC, Lan K. Evaluation of serum anti-mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle[J]. Int J Clin Exp Pathol, 2014, 7:6245-6253.
  • 5Nakhuda GS, Sauer MV, Wang JG, Ferin M, Lobo RA. Mullerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF[J]. Reprod Biomed Online, 2007, 14:450-454.
  • 6Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti- Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos[J]. Eur J Obstet Gynecol Reprod Biol, 2010, 150:166-170.
  • 7Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve[J]. Fertil Steril, 2010, 94:2824-2827.
  • 8Lehmann P, Velez MP, Saumet J, Lapensee L, Jamal W, Bissonnette F, Phillips S, Kadoch IJ. Anti-Mullerian hormone (AMH) :a reliable biomarker of oocyte quality in IVF[J]. J Assist Reprod Genet, 2014, 31:493-498.
  • 9Koshy AK, Gudi A, Shah A, Bhide P, Timms P, Homburg R. Pregnancy prognosis in women with anti-Mullerian hormone below the tenth percentile[J]. Gynecol Endocrinol, 2013,29 662-665.
  • 10Fanchin R, Mendez LD, Frydman N, Gougeon A, di Clemente N, Frydman R, Taieb J. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization[J]. J Clin Endocrinol Metab, 2007,92 : 1796-1802.

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部